Last reviewed · How we verify
NCT07241195: MAPS Cohort
A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes
trial in NAFLD and NASH in 20,000 participants. Not yet recruiting.
31 December 2030
Quick facts
| Lead sponsor | The Affiliated Hospital of Hangzhou Normal University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 20,000 |
| Start date | 12 March 2026 |
| Primary completion | 31 December 2030 |
| Estimated completion | 31 December 2030 |
Conditions studied
- NAFLD and NASH — all drugs for NAFLD and NASH →
- NAFLD( Non-alcoholic Fatty Liver Disease ) — all drugs for NAFLD( Non-alcoholic Fatty Liver Disease ) →
- NAFLD Cirrhosis — all drugs for NAFLD Cirrhosis →
Sponsor
The Affiliated Hospital of Hangzhou Normal University
Who can join
Adults 65 to 100, any sex, with NAFLD and NASH or NAFLD( Non-alcoholic Fatty Liver Disease ). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To establish a cohort of elderly fatty liver disease based on the community medical examination population. Through the large-scale cohort study, the risk factors affecting fatty liver in the elderly will be explored in depth from the aspects of lifestyle, environment and genetics, the development pattern and mechanism of fatty liver in the elderly will be analysed, and the health risk assessment system and Chinese standard for fatty liver in the elderly covering cardiovascular risk, risk of hepatic fibrosis and risk of sarcopenia will be established, so as to provide the scientific basis for the precise intervention of fatty liver in the elderly in China.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07241195
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Affiliated Hospital of Hangzhou Normal University trials
Trials by the same sponsor.
- NCT07399600 — Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease · NA · not yet recruiting
- NCT07233486 — A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD · NA · recruiting
- NCT06201572 — The Value of TOI in Evaluating Renal Function Damage in Hypertensive Emergency Patients · unknown
- NCT06135584 — Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07241195 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Hangzhou Normal University
- Last refreshed: 21 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07241195.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing